)
Summary of poster presentation:
- TSND-201 increases neurite outgrowth and branching via well-studied mechanisms (i.e., monoamines, neurotrophins, and mTor).
- Preclinical results add to understanding of TSND-201’s mechanism of action.
- Demonstrates direct neurotrophic effects of TSND-201 for the first time.
- Confirms that neuroplastic effects are mediated by TSND-201’s known pharmacological targets (serotonin, norepinephrine, dopamine transporters) – connecting the dots between primary pharmacology and long-lasting neuroplasticity.
- Underscores TSND-201’s potential as a rapid, robust, and long-lasting pharmacotherapy for PTSD and other CNS disorders.
